Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

Doraya

financed

Closed

Doraya is an innovative catheter device for treating patients resistant to diure...

Doraya is an innovative catheter device for treating patients resistant to diuretics with Acute Heart Failure AHF condition. Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includes difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting mill... see more

30/04/2019

Rveamp Medical

71K€

Project Budget: 71K€

Project leader

REVAMP MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-04-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada does 5 years

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Rveamp Medical

50.00K€ | Leader

ADVANTIC SISTEMAS Y SERVICIO...

215.73K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 2 months Date Start: 2019-01-31
End date: 2019-04-30

Project leader

REVAMP MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 71K€

participation deadline Sin fecha límite de participación.

Project description Acute Heart Failure (AHF) is a sudden worsening of the signs and symptoms of chronic heart failure, which typically includes difficulty in breathing, leg or feet swelling and fatigue. HF is a growing global problem, affecting millions of people around the world (present in 1%-12% in Europe and the United States. The lifetime risk of developing the disease ranging in between 20%-33%). AHF is the most common cause of hospitalization for patients older than 65 years of age. Over the last 3 decades, the hospitalization rates for patients with AHF has tripled and is expected to increase. An ageing population will increase the prevalence of AHF, which in turn will lead to significant monetary expenses. Fluid decongestion is the key treatment of AHF, where 90% of patients are treated with diuretics. However, 30%-40% of patients are resistant to diuretics. The DorayaTM is the first device to directly create an optimal hemodynamic environment, enabling diuretic efficiency to relieve congestion and restore organ function. The DorayaTM catheter regulates vascular hemodynamics in AHF patients, including those who have developed diuretic resistance. Chronic Heart Failure market is expected to increase from €2.64bn in 2015 to €8.78bn in 2025, which represents a 12.9% of CAGR. Since, AHF market accounts for 75% of the total Chronic Heart Failure market, the total available global market by 2025 is expected to reach €6.59bn. With 30% of patients resistant to diuretics, this represents a huge unmet market that Doraya can service.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers